Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;99(10):2045-54.
doi: 10.1111/j.1349-7006.2008.00903.x.

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients

Suman Lal  1 , Edwin Sandanaraj, Zee Wan Wong, Peter C S Ang, Nan Soon Wong, Edmund J D Lee, Balram Chowbay
Affiliations

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients

Suman Lal et al. Cancer Sci. 2008 Oct.

Abstract

The present study aimed to identify polymorphic genes encoding carbonyl reductases (CBR1, CBR3) and investigate their influence on doxorubicin disposition in Asian breast cancer patients (n = 62). Doxorubicin (60 mg/m(2)) was administered every 3 weeks for four to six cycles and the pharmacokinetic parameters were estimated using non-compartmental analysis (WinNonlin). The Mann-Whitney U-test was used to assess genotypic-phenotypic correlations. Five CBR1 (-48G>A, c.219G>C, c.627C>T, c.693G>A, +967G>A) and CBR3 (c.11G>A, c.255C>T, c.279C>T, c.606G>A, c.730G>A) polymorphisms were identified. The CBR1 D2 diplotypes were characterized by the presence of at least one variant allele at the c.627C>T and +967G>A loci. Patients in the CBR1 D1 diplotype group had significantly higher clearance (CL) normalized to body surface area (BSA) (CL/BSA[L/h/m(2)]: median 25.09; range 16.44-55.66) and significantly lower exposure levels; area under curve (AUC(0-infinity)/dose/BSA [h/m(5)]; median 15.08; range 6.18-38.03) of doxorubicin compared with patients belonging to the CBR1 D2 diplotype group (CL/BSA[L/h/m(2)]; median 20.88; range 8.68-31.79, P = 0.014; and AUC(0-infinity)/dose/BSA[h/m(5)]; median 21.35; range 9.82-67.17, P = 0.007 respectively). No significant influence of CBR3 polymorphisms on the pharmacokinetics of doxorubicin were observed in Asian cancer patients. The present exploratory study shows that CBR1 D2 diplotypes correlate with significantly higher exposure levels of doxorubicin, suggesting the possibility of lowered intracellular conversion to doxorubicinol in these patients. Further evaluation of carbonyl reductase polymorphisms in influencing the treatment efficacy of doxorubicin-based chemotherapy in Asian cancer patients are warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pairwise linkage disequilibrium among (a) CBR1 and (b) CBR3 polymorphisms in Asian breast cancer patients.
Figure 2
Figure 2
CBR1 diplotype groups observed in Asian breast cancer patients.
Figure 3
Figure 3
Influence of CBR1 diplotypes on (a) clearance and (b) exposure levels of doxorubicin in Asian breast cancer patients. N, number of subjects.
See this image and copyright information in PMC

References

    1. Guengerich FP. Cytochrome P450. Structure, Mechanism, and Biochemistry, 2nd edn. New York: Plenum Press, 1995.
    1. Felsted RL, Richter DR, Bachur NR. Rat liver aldehyde reductase. Biochem Pharmacol 1977; 26: 1117–24. - PubMed
    1. Felsted RL, Bachur NR. Mammalian carbonyl reductases. Drug Metab Rev 1980; 11: 1–60. - PubMed
    1. Forrest GL, Gonzalez B. Carbonyl reductase. Chem Biol Interact 2000; 129: 21–40. - PubMed
    1. Tanaka M, Bateman R, Rauh D et al . An unbiased cell morphology‐based screen for new, biologically active small molecules. PLoS Biol 2005; 3: e128. - PMC - PubMed

Publication types

MeSH terms